GlassScriptPhysician profile
Jennifer M Murphy
NPI 1548812829
$1,884.11
in general payments reported to CMS, 2019-2025
25 companies · $744 in 2025
The $744 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.81 · 2022: $147 · 2023: $186 · 2024: $793 · 2025: $744.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,198 · Education: $526.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,197.80 |
| Education | $525.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $423.44 | 2022-2025 | Padcev, Xtandi, Xospata |
| Daiichi Sankyo INC. | $229.16 | 2023-2025 | Enhertu |
| Merck Sharp & Dohme LLC | $120.17 | 2024-2025 | Keytruda |
| Stryker Corporation | $102.54 | 2025 | Surgicount |
| Seagen INC. | $99.99 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $85.50 | 2023-2025 | Lynparza, Enhertu, Calquence |
| Sanofi-Aventis U.S. LLC | $84.75 | 2025 | |
| Pharmaessentia USA Corporation | $81.37 | 2023-2024 | Besremi |
| E.R. Squibb & Sons, L.L.C. | $65.85 | 2022-2025 | Opdivo |
| Celgene Corporation | $62.40 | 2022-2025 | Reblozyl |
| Taiho Oncology, INC. | $60.49 | 2024-2025 | |
| Genentech USA, INC. | $56.27 | 2024-2025 | Polivy, Tecentriq, Phesgo |
| Bayer Healthcare Pharmaceuticals INC. | $55.86 | 2024-2025 | |
| Glaxosmithkline, LLC. | $51.30 | 2023-2025 | Zejula, Jemperli, Ojjaara |
| Genzyme Corporation | $50.92 | 2024-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $44.16 | 2022-2025 | |
| Aveo Pharmaceuticals, INC. | $40.51 | 2025 | |
| Servier Pharmaceuticals LLC | $33.20 | 2024 | |
| Janssen Biotech, INC. | $29.37 | 2024 | Imbruvica, Darzalex, Tecvayli |
| Beone Medicines USA, INC. | $22.75 | 2025 | Brukinsa |
| Blue Earth Diagnostics | $21.49 | 2025 | Posluma |
| Stemline Therapeutics INC. | $17.25 | 2025 | Orserdu |
| Beigene USA, INC. | $16.11 | 2024 | Brukinsa |
| Alexion Pharmaceuticals, INC. | $15.45 | 2024 | Ultomiris |
| Karyopharm Therapeutics INC. | $13.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.